Wall Street brokerages expect OptiNose Inc (NASDAQ:OPTN) to announce $4.35 million in sales for the current quarter, according to Zacks. Two analysts have issued estimates for OptiNose’s earnings. The lowest sales estimate is $4.30 million and the highest is $4.39 million. OptiNose posted sales of $870,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 400%. The company is expected to announce its next quarterly earnings report before the market opens on Monday, May 13th.
According to Zacks, analysts expect that OptiNose will report full-year sales of $36.51 million for the current fiscal year, with estimates ranging from $35.30 million to $37.73 million. For the next fiscal year, analysts forecast that the company will post sales of $84.42 million, with estimates ranging from $78.50 million to $90.35 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover OptiNose.
OptiNose (NASDAQ:OPTN) last issued its quarterly earnings results on Wednesday, March 6th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.20. OptiNose had a negative net margin of 1,509.87% and a negative return on equity of 77.32%. The business had revenue of $3.02 million for the quarter, compared to analysts’ expectations of $2.60 million.
Shares of OPTN stock traded up $0.37 during trading hours on Tuesday, hitting $9.83. 139,312 shares of the company were exchanged, compared to its average volume of 157,903. The company has a debt-to-equity ratio of 0.61, a quick ratio of 8.01 and a current ratio of 8.28. OptiNose has a one year low of $5.66 and a one year high of $30.00. The stock has a market capitalization of $405.63 million, a price-to-earnings ratio of -3.67 and a beta of 0.81.
Several institutional investors and hedge funds have recently added to or reduced their stakes in OPTN. BlackRock Inc. raised its holdings in shares of OptiNose by 69.0% during the fourth quarter. BlackRock Inc. now owns 1,820,167 shares of the company’s stock valued at $11,285,000 after buying an additional 743,369 shares during the last quarter. Broadfin Capital LLC bought a new stake in shares of OptiNose during the fourth quarter valued at approximately $4,406,000. JPMorgan Chase & Co. raised its holdings in shares of OptiNose by 39.1% during the third quarter. JPMorgan Chase & Co. now owns 1,874,231 shares of the company’s stock valued at $23,297,000 after buying an additional 526,501 shares during the last quarter. Kornitzer Capital Management Inc. KS raised its holdings in shares of OptiNose by 1,262.9% during the fourth quarter. Kornitzer Capital Management Inc. KS now owns 477,005 shares of the company’s stock valued at $2,957,000 after buying an additional 442,005 shares during the last quarter. Finally, Foresite Capital Management IV LLC raised its holdings in shares of OptiNose by 17.1% during the fourth quarter. Foresite Capital Management IV LLC now owns 1,708,545 shares of the company’s stock valued at $10,593,000 after buying an additional 250,000 shares during the last quarter. 56.90% of the stock is currently owned by institutional investors.
OptiNose Company Profile
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Featured Story: What is a recession?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.